Frontal cortex chitinase and pentraxin neuroinflammatory alterations during the progression of Alzheimer's disease.


Journal

Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974

Informations de publication

Date de publication:
17 Feb 2020
Historique:
received: 21 10 2019
accepted: 20 01 2020
entrez: 19 2 2020
pubmed: 19 2 2020
medline: 15 12 2020
Statut: epublish

Résumé

Chitinase 3-like 1 (CHI3L1), chitinase 3-like 2 (CHI3L2), and neuronal pentraxin II (NPTX2) are inflammatory biomarkers of Alzheimer's disease (AD). Although studies have demonstrated that cerebrospinal fluid levels of these proteins are changed in AD, no studies have undertaken a detailed examination of alterations in protein levels, cellular expression, and interaction with amyloid in the brain during the progression of AD. The study evaluated levels of both CHI3L1 and CHI3L2, NPTX2, ionized calcium-binding adapter molecule 1 (Iba1), complement component 1q (C1q), glial fibrillary acidic protein (GFAP), and CD44, in the frontal cortex of people who died with an antemortem clinical diagnosis of no cognitive impairment (NCI), mild cognitive impairment (MCI), mild/moderate AD (mAD), and severe AD (sAD) using immunoblot and immunohistochemical techniques. CHI3L1-immunoreactive (-ir) astrocyte numbers were increased in the frontal cortex and white matter in sAD compared to NCI. On the other hand, increases in GFAP and Iba1-ir cell numbers were observed in MCI compared to NCI but only in white matter. Western blot analyses revealed significantly lower frontal cortex CHI3L2 levels, whereas CD44 levels were increased in sAD. No significant differences for CHI3L1, GFAP, C1q, and NPTX2 protein levels were detected between clinical groups. Strong significant correlations were found between frontal cortex CHI3L1 and Iba1-ir cell numbers in white matter and CHI3L1 and C1q protein levels in the early stages of the disease. C1q and Iba1, CD44 with CHI3L2, and GFAP protein levels were associated during disease progression. CHI3L1 and Iba1 cell numbers in white matter showed a significant associations with episodic memory and perceptual speed. White matter CHI3L1 inflammatory response is associated with cognitive impairment early in the onset of AD.

Sections du résumé

BACKGROUND BACKGROUND
Chitinase 3-like 1 (CHI3L1), chitinase 3-like 2 (CHI3L2), and neuronal pentraxin II (NPTX2) are inflammatory biomarkers of Alzheimer's disease (AD). Although studies have demonstrated that cerebrospinal fluid levels of these proteins are changed in AD, no studies have undertaken a detailed examination of alterations in protein levels, cellular expression, and interaction with amyloid in the brain during the progression of AD.
METHODS METHODS
The study evaluated levels of both CHI3L1 and CHI3L2, NPTX2, ionized calcium-binding adapter molecule 1 (Iba1), complement component 1q (C1q), glial fibrillary acidic protein (GFAP), and CD44, in the frontal cortex of people who died with an antemortem clinical diagnosis of no cognitive impairment (NCI), mild cognitive impairment (MCI), mild/moderate AD (mAD), and severe AD (sAD) using immunoblot and immunohistochemical techniques.
RESULTS RESULTS
CHI3L1-immunoreactive (-ir) astrocyte numbers were increased in the frontal cortex and white matter in sAD compared to NCI. On the other hand, increases in GFAP and Iba1-ir cell numbers were observed in MCI compared to NCI but only in white matter. Western blot analyses revealed significantly lower frontal cortex CHI3L2 levels, whereas CD44 levels were increased in sAD. No significant differences for CHI3L1, GFAP, C1q, and NPTX2 protein levels were detected between clinical groups. Strong significant correlations were found between frontal cortex CHI3L1 and Iba1-ir cell numbers in white matter and CHI3L1 and C1q protein levels in the early stages of the disease. C1q and Iba1, CD44 with CHI3L2, and GFAP protein levels were associated during disease progression. CHI3L1 and Iba1 cell numbers in white matter showed a significant associations with episodic memory and perceptual speed.
CONCLUSIONS CONCLUSIONS
White matter CHI3L1 inflammatory response is associated with cognitive impairment early in the onset of AD.

Identifiants

pubmed: 32066474
doi: 10.1186/s12974-020-1723-x
pii: 10.1186/s12974-020-1723-x
pmc: PMC7025403
doi:

Substances chimiques

CHI3L1 protein, human 0
Chitinase-3-Like Protein 1 0
Inflammation Mediators 0
Nerve Tissue Proteins 0
neuronal pentraxin 0
C-Reactive Protein 9007-41-4
CHI3L2 protein, human EC 3.2.1.14
Chitinases EC 3.2.1.14

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

58

Subventions

Organisme : NIA NIH HHS
ID : P30 AG010161
Pays : United States
Organisme : NIA NIH HHS
ID : PO1AG014449
Pays : United States
Organisme : NIA NIH HHS
ID : P30AG019610
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG019610
Pays : United States
Organisme : NIA NIH HHS
ID : R01AG043375
Pays : United States

Références

Alzheimers Dement. 2019 Jun;15(6):742-753
pubmed: 30967340
Sci Rep. 2019 Mar 18;9(1):4749
pubmed: 30894627
Mediators Inflamm. 2018 Nov 11;2018:2530414
pubmed: 30533998
Arch Neurol. 2004 Mar;61(3):378-84
pubmed: 15023815
Curr Alzheimer Res. 2012 Jul;9(6):724-33
pubmed: 22471862
Front Aging Neurosci. 2018 Nov 13;10:359
pubmed: 30542277
Virus Res. 2017 Jan 2;227:220-230
pubmed: 27794455
Elife. 2017 Mar 23;6:
pubmed: 28440221
Am J Pathol. 2012 Feb;180(2):526-40
pubmed: 22142809
J Neurosci Res. 1994 Nov 1;39(4):398-404
pubmed: 7884819
J Alzheimers Dis. 2015;50(3):873-86
pubmed: 26836182
Alzheimers Dement. 2016 Apr;12(4):459-509
pubmed: 27570871
Neurobiol Aging. 2000 May-Jun;21(3):383-421
pubmed: 10858586
Neuron. 2003 Jul 31;39(3):513-28
pubmed: 12895424
Front Immunol. 2018 Apr 10;9:764
pubmed: 29692784
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6448-53
pubmed: 9600986
Exp Cell Res. 2003 Jul 1;287(1):79-87
pubmed: 12799184
BMC Geriatr. 2018 Nov 14;18(1):280
pubmed: 30428832
J Neurol Sci. 2016 Oct 15;369:242-249
pubmed: 27653898
Clin Sci (Lond). 2017 Mar 1;131(6):425-437
pubmed: 28265034
Front Integr Neurosci. 2013 Aug 13;7:59
pubmed: 23964211
Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S91-4
pubmed: 9330994
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Neurobiol Aging. 2016 Jan;37:147-153
pubmed: 26686670
Acta Neuropathol. 2012 Jan;123(1):13-30
pubmed: 22101321
Neurology. 2005 Mar 8;64(5):834-41
pubmed: 15753419
Neurobiol Aging. 2017 Jun;54:133-143
pubmed: 28365005
Brain Behav Immun. 2016 Nov;58:201-208
pubmed: 27444967
J Alzheimers Dis. 2018;62(3):1199-1209
pubmed: 29562530
Alzheimers Dement. 2019 May;15(5):644-654
pubmed: 30853464
JAMA Neurol. 2016 Jan;73(1):60-7
pubmed: 26524180
Neurosci Lett. 2019 Jul 13;705:183-194
pubmed: 31028844
J Neurosci. 2005 Aug 24;25(34):7709-17
pubmed: 16120771
Eur Neurol. 2000;44(4):229-35
pubmed: 11096223
Brain Res Bull. 2003 Aug 15;61(3):255-60
pubmed: 12909295
Ann Neurol. 2018 Mar;83(3):544-552
pubmed: 29406582
Mov Disord. 2016 Jun;31(6):898-905
pubmed: 26878815
J Exp Clin Cancer Res. 2018 Aug 30;37(1):208
pubmed: 30165890
Clin Cancer Res. 2009 Dec 15;15(24):7462-7468
pubmed: 20008845
Neurology. 1991 Jul;41(7):1006-9
pubmed: 2067629
Arch Pediatr Adolesc Med. 1995 May;149(5):559-64
pubmed: 7735413
Eur J Neurol. 2016 May;23(5):898-905
pubmed: 26872061
Neuron. 1999 Jun;23(2):309-23
pubmed: 10399937
Science. 2016 May 6;352(6286):712-716
pubmed: 27033548
Alzheimers Dement. 2017 Jan;13(1):1-7
pubmed: 27583652
J Neuropathol Exp Neurol. 2012 Nov;71(11):1018-29
pubmed: 23095849
Front Cell Neurosci. 2014 Nov 03;8:362
pubmed: 25404894
Novartis Found Symp. 2006;279:80-6; discussion 86-91, 216-9
pubmed: 17278387
J Histochem Cytochem. 2000 Dec;48(12):1627-38
pubmed: 11101631
J Neuropathol Exp Neurol. 1999 Nov;58(11):1147-55
pubmed: 10560657
J Neurotrauma. 2010 Jul;27(7):1215-23
pubmed: 20486806
Arch Neurol. 2001 Sep;58(9):1403-8
pubmed: 11559311
Oncoimmunology. 2018 Mar 13;7(6):e1436922
pubmed: 29872578
J Neurosci. 2017 Feb 1;37(5):1062-1080
pubmed: 27986928
J Alzheimers Dis. 2018;66(2):439-444
pubmed: 30282354
Expert Rev Neurother. 2008 Dec;8(12):1879-91
pubmed: 19086882
Annu Rev Immunol. 2005;23:337-66
pubmed: 15771574
J Neuroimmunol. 2014 Sep 15;274(1-2):86-95
pubmed: 25005116
J Neurosci. 2009 Feb 11;29(6):1860-73
pubmed: 19211893
Mol Neurodegener. 2017 Nov 10;12(1):83
pubmed: 29126445
Am J Pathol. 2008 Jul;173(1):130-43
pubmed: 18556781
JAMA. 1995 Apr 26;273(16):1274-8
pubmed: 7646655
Int J Neurosci. 1991 Apr;57(3-4):167-78
pubmed: 1938160
Neurol Sci. 2015 Oct;36(10):1881-8
pubmed: 26037549
J Alzheimers Dis. 2017;59(3):903-912
pubmed: 28697565
Neurobiol Aging. 2014 Dec;35(12):2671-2680
pubmed: 25002037
Neurotox Res. 2016 Jul;30(1):53-66
pubmed: 26892644
FEBS Lett. 1994 Aug 29;351(1):80-4
pubmed: 8076698
J Neurosci. 2014 Feb 5;34(6):2285-98
pubmed: 24501367
Neuroimage Clin. 2014 Feb 19;4:604-14
pubmed: 24936411
Arch Neurol. 1995 Jun;52(6):612-9
pubmed: 7763211
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3228-33
pubmed: 10077666
Inflammopharmacology. 2019 Aug;27(4):663-677
pubmed: 30874945
Proc Natl Acad Sci U S A. 1989 Oct;86(19):7611-5
pubmed: 2529544
Arch Neurol. 1989 Apr;46(4):379-82
pubmed: 2650663
Trends Neurosci. 2001 Apr;24(4):219-24
pubmed: 11250006
Transl Neurodegener. 2018 Sep 10;7:23
pubmed: 30311914
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Neurology. 2006 Jun 27;66(12):1837-44
pubmed: 16801647
J Neuroinflammation. 2017 Jun 9;14(1):118
pubmed: 28599675
Transl Neurodegener. 2013 Oct 12;2(1):21
pubmed: 24119446
J Neuroimmunol. 1989 Oct;24(3):173-82
pubmed: 2808689
Neuropathology. 2015 Apr;35(2):95-106
pubmed: 25377763
Mult Scler Relat Disord. 2018 Aug;24:175-183
pubmed: 30055504
J Neuroinflammation. 2010 Jun 11;7:34
pubmed: 20540736
J Neuroinflammation. 2018 Jul 18;15(1):209
pubmed: 30021640
Int J Mol Sci. 2019 May 10;20(9):
pubmed: 31083327
Neurodegener Dis. 2010;7(1-3):143-7
pubmed: 20197694
J Comp Neurol. 2016 May 1;524(7):1309-36
pubmed: 26780384
J Neuropathol Exp Neurol. 1999 Apr;58(4):376-88
pubmed: 10218633
Dement Geriatr Cogn Dis Extra. 2019 Mar 12;9(1):100-113
pubmed: 31011328
Brain Res. 1993 Dec 31;632(1-2):249-59
pubmed: 7511977
Alzheimers Dement. 2016 Jun;12(6):719-32
pubmed: 27179961
J Am Geriatr Soc. 1997 Mar;45(3):321-8
pubmed: 9063278
Behav Brain Res. 2018 Jul 16;347:49-56
pubmed: 29462653
Alzheimers Res Ther. 2015 Sep 17;7(1):59
pubmed: 26383836
Neurobiol Aging. 2016 Jul;43:101-10
pubmed: 27255819
Acta Neuropathol. 2012 Jan;123(1):1-11
pubmed: 22101365
Annu Rev Immunol. 2014;32:433-59
pubmed: 24499275
Mol Psychiatry. 2011 Sep;16(9):908-16
pubmed: 20820167
Curr Neuropharmacol. 2017;15(6):906-917
pubmed: 28183245
Biomed Pharmacother. 2018 Apr;100:478-485
pubmed: 29477911
J Biol Chem. 2017 Feb 17;292(7):2624-2636
pubmed: 28053085
Biol Psychiatry. 2015 Apr 15;77(8):693-703
pubmed: 24529280
Exp Neurol. 1999 Aug;158(2):469-90
pubmed: 10415154
J Clin Neurosci. 2019 Jun;64:220-226
pubmed: 30948312

Auteurs

Marta Moreno-Rodriguez (M)

Department of Neurobiology and Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, 350 W. Thomas Rd., Phoenix, AZ, 85013, USA.

Sylvia E Perez (SE)

Department of Neurobiology and Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, 350 W. Thomas Rd., Phoenix, AZ, 85013, USA.

Muhammad Nadeem (M)

Department of Neurobiology and Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, 350 W. Thomas Rd., Phoenix, AZ, 85013, USA.

Michael Malek-Ahmadi (M)

Banner Alzheimer's Institute, Phoenix, AZ, USA.

Elliott J Mufson (EJ)

Department of Neurobiology and Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, 350 W. Thomas Rd., Phoenix, AZ, 85013, USA. Elliott.mufson@dignityhealth.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH